Dr. Komissarov earned both his MS and PhD degree at the Lomonosov Moscow State University and was an Assistant Professor in the Chemistry Department. His research and teaching activities at Moscow State University were focused on the mechanisms of enzymatic reactions and the use of radioactive tags in chemistry and biology. After over a decade at Moscow State University he joined the Institute for Genetics and Selection of Industrial Microorganisms—now a part of the Federal Kurchatov Center— as a Senior Scientist, where he applied his understanding of enzymes to developing novel anti-cancer therapeutics. After moving to the United States he continued his research at the University of Missouri, Columbia; HFHS, Detroit; and Portland State University. He joined the University of Texas Health Science Center at Tyler (UTHSCT) in 2007.

Dr. Komissarov brought to UTHSCT his extensive research experience and teaching skills, as well as a thorough understanding of the enzymes and the inhibitors that control the fibrinolytic system. His focus on understanding the molecular interactions in fibrinolysis resulted in the identification of a serpin, Plasminogen Activator Inhibitor 1 (PAI-1) as a molecular target in the therapy of pleural injury. PAI-1 neutralization results in an up to 8-fold increase in the efficacy of fibrinolytic therapy in animal models. His current research is focused on furthering our understanding of the mechanisms of fibrinolysis and the development of novel inhibitors of PAI-1 as well as approaches to improve therapeutic outcomes. A prototype (FPA96F) of a novel Point of Care (POC) diagnostic test– the Fibrinolytic Potential Assay (FPA, US Patent #10175255)— a companion bedside test to personalize therapy of empyema was tested and validated in an animal model and human samples of pleural fluid. Currently, Dr. Komissarov is working on adapting a FPA96F prototype test to the rural hospitals’ settings. Other Projects Include (i) characterization of effects of nanobodies and phage display selected peptides on plasminogen activation and fibrinolysis; (ii) use of imaging modalities and nanocarriers (liposomal and “molecular cage” type) to improve fibrinolysis; (iii) evaluating the effect of ligands of different nature incorporated into fibrin on the rate of fibrinolysis; (iv) determining the role of inhibition of the fibrinolytic system in lung injury caused by mustard gas or industrial alkylating agents; (v) studying perfluorcarbons as potential carriers for the delivery of fibrinolytic drugs to smoke injured lungs; (vi) analyzing molecular signatures in human and animal samples. Biotechnology projects are focused on development, formulation, characterization and stabilization of novel therapeutics. Dr. Komissarov has co-authored almost 60 publications in peer-reviewed journals, and has 25 presentations over the last 2 years.

Dr. Komissarov teaches multiple classes and labs in the Biotechnology Master’s Program at UTHSCT. He mentors summer interns and volunteers, and also visits Tyler Classical Academy to present a Career Choice Talk. His teaching philosophy focuses on providing mentorship, early opportunities for personal development and professional advancement, and providing age- and training-appropriate research experiences for young future scientists. The range spans from K-12 through undergraduate, graduate, and post-graduate levels. Every year his mentees win scholarships and travel grants to participate in international and local meetings with posters and oral presentations. His hobbies include traveling, skiing, photography, and protein chemistry in the kitchen. He enjoys running with students— from a 5K to a Half Marathon distance.

Education and Training

Moscow State University, Moscow, USSR
MS, Chemistry, 1980
Moscow State University, Moscow, USSR
PhD, Chemistry of Natural Compounds, 1988

Courses Taught

Biotechnology Master Program at UTHSCT, team lecturer
BIOT 5221, Proteins and Nucleic Acids
BIOT 5222, Advanced Metabolism
BIOT 5222L, Advanced Metabolism (lab)
BIOT 5310, Fundamentals of Biomedical Research
BIOT 6312, Advanced Techniques in Protein Chemistry
BIOT 6312L, Advanced Techniques in Protein Chemistry (lab)
BIOT 5211, Advanced Biotechniques
BIOT 5211L, Advanced Biotechniques (lab)
BIOT 5331, Advanced Graduate Studies I
BIOT 5332, Advanced Graduate Studies II
BIOT 6331, Thesis Research
BIOT 6332, Thesis Writing
BIOT 5132, Critical Reading
Graduate Students’ Mentor and Thesis Committee Member.

Research Interests

Molecular Interactions of Fibrinolysis (MIF) - “From Bench to Bedside and Back”.
Use Precise Molecular Targeting to Increase the Efficacy of Therapy. Testing Two Targets Concept in Chronic Empyema Model.
Evolving of Novel Diagnostic Fibrinolytic Potential Assay (FPA96F) into a Point of Care (POC) Test to Personalize Fibrinolytic Therapy.
Selection, Evaluation the Mechanisms of Modulation of Serpin Activity by Nanobodies and Phage Display Derived Peptides.
Employing Liposomal Nanoparticles and Molecular Cage Type Complexes for Precise Delivery of Therapeutics.
Study Effects of Ultrasonography, and Computer Tomography on Fibrinolysis and Fibrin Structure in vitro and in vivo.
Study of Molecular Signatures in Samples from Animal Models and Humans to Improve Diagnostics and Therapeutic Strategies with Novel Biomarkers and Molecular Targets.

Recent Publications

Sillen, M., Weeks, S., Zhou, X., Komissarov, A., Florova, G., Idell, S., Strelkov, S., Declerck, P. J. Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction. J Thromb Haemost. 18: 681-692, 2020.
Girard RA, Chauhan PS, Tucker TA, Allen T, Kaur J, Jeffers A, Koenig K, Florova G, Komissarov AA, Gaidenko TA, Chamiso MB, Fowler J, Morris DE, Sarva K, Singh KP, Idell S, Idell RD. Increased expression of plasminogen activator inhibitor-1 (PAI-1) is associated with depression and depressive phenotype in C57Bl/6J mice. Exp Brain Res. 237: 3419-3430, 2019.
Beckert L, Brockway B, Simpson G, Southcott AM, Lee YCG, Rahman N, Light RW, Shoemaker S, Gillies J, Komissarov AA, Florova G, Ochran T, Bradley W, Ndetan H, Singh KP, Sarva K, Idell S. Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema. JCI Insight. Apr 18;5. pii: 127470. doi: 10.1172/jci.insight.127470, 2019.
Florova G, Azghani AO, Karandashova S, Schaefer C, Yarovoi SV, Declerck PJ, Cines DB, Idell S and Komissarov AA. Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits. Am J Physiol Lung Cell Mol Physiol 314: L54-L68, 2018.
Fukuda S, Enkhbaatar P, Nelson C, Cox RA, Wolfson MR, Shaffer TH, Williams RO, III, Surasarang SH, Sawittree S, Florova G, Komissarov AA, Koenig K, Sarva K, Ndetan HT, Singh KP and Idell S. Lack of durable protection against cotton smoke-induced acute lung injury in sheep by nebulized single chain urokinase plasminogen activator or tissue plasminogen activator.Clin Transl Med 7: 17, 2018.
Hengsawas SS, Florova G, Komissarov AA, Shetty S, Idell S and Williams RO, III. Formulation for a novel inhaled peptide therapeutic for idiopathic pulmonary fibrosis. Drug Dev Ind Pharm 44: 184-198, 2018.
Komissarov AA, Rahman N, Lee YCG, Florova G, Shetty S, Idell R, Ikebe M, Das K, Tucker TA and Idell S. Fibrin turnover and pleural organization: bench to bedside. Am J Physiol Lung Cell Mol Physiol 314: L757-L768, 2018.
Surasarang SH, Sahakijpijarn S, Florova G, Komissarov AA, Nelson CL, Perenlei E, Fukuda S, Wolfson MR, Shaffer TH, Idell S and Williams RO, III. Nebulization of Single-Chain Tissue-Type and Single-Chain Urokinase Plasminogen Activator for Treatment of Inhalational Smoke-Induced Acute Lung Injury. J Drug Deliv Sci Technol 48: 19-27, 2018.